NEW YORK (GenomeWeb News) – Biopharmaceutical firm Berg and the US Department of Defense today announced an agreement to discover biomarkers for prostate cancer and to develop more effective treatments for the disease.

The deal is in the form of a Cooperative Research and Development agreement with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.